Global GLP-1 for Diabetes Market Growth 2025-2031
Description
The global GLP-1 for Diabetes market size is predicted to grow from US$ 26760 million in 2025 to US$ 47290 million in 2031; it is expected to grow at a CAGR of 10.0% from 2025 to 2031.
GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone in the body that plays a crucial role in glucose homeostasis. It is released from the intestine in response to food intake and stimulates the release of insulin from pancreatic beta cells. The primary function of insulin is to help cells in the body take up glucose, thereby lowering blood sugar levels.
Increasing Adoption of GLP-1 Receptor Agonists: GLP-1 receptor agonists were gaining popularity in the management of type 2 diabetes. These medications were recognized for their ability to improve glycemic control, stimulate insulin secretion, and offer potential benefits such as weight loss.
Development of New GLP-1 Therapies: Pharmaceutical companies were actively engaged in the research and development of new GLP-1 receptor agonists with improved formulations, longer durations of action, and enhanced patient adherence. This innovation aimed to provide more options for patients and healthcare providers.
Combination Therapies: The use of GLP-1 receptor agonists in combination with other classes of antidiabetic medications, such as SGLT-2 inhibitors or DPP-4 inhibitors, was explored to achieve better glycemic control and address multiple aspects of diabetes pathology.
Market Competition: The landscape for diabetes medications, including GLP-1 receptor agonists, was becoming more competitive. Competition often drives innovation and may lead to improved treatment options and cost-effectiveness.
LP Information, Inc. (LPI) ' newest research report, the “GLP-1 for Diabetes Industry Forecast” looks at past sales and reviews total world GLP-1 for Diabetes sales in 2024, providing a comprehensive analysis by region and market sector of projected GLP-1 for Diabetes sales for 2025 through 2031. With GLP-1 for Diabetes sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 for Diabetes industry.
This Insight Report provides a comprehensive analysis of the global GLP-1 for Diabetes landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GLP-1 for Diabetes portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GLP-1 for Diabetes market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 for Diabetes and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 for Diabetes.
This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 for Diabetes market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Injection
Oral Agent
Segmentation by Application:
Woman
Man
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Key Questions Addressed in this Report
What is the 10-year outlook for the global GLP-1 for Diabetes market?
What factors are driving GLP-1 for Diabetes market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do GLP-1 for Diabetes market opportunities vary by end market size?
How does GLP-1 for Diabetes break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone in the body that plays a crucial role in glucose homeostasis. It is released from the intestine in response to food intake and stimulates the release of insulin from pancreatic beta cells. The primary function of insulin is to help cells in the body take up glucose, thereby lowering blood sugar levels.
Increasing Adoption of GLP-1 Receptor Agonists: GLP-1 receptor agonists were gaining popularity in the management of type 2 diabetes. These medications were recognized for their ability to improve glycemic control, stimulate insulin secretion, and offer potential benefits such as weight loss.
Development of New GLP-1 Therapies: Pharmaceutical companies were actively engaged in the research and development of new GLP-1 receptor agonists with improved formulations, longer durations of action, and enhanced patient adherence. This innovation aimed to provide more options for patients and healthcare providers.
Combination Therapies: The use of GLP-1 receptor agonists in combination with other classes of antidiabetic medications, such as SGLT-2 inhibitors or DPP-4 inhibitors, was explored to achieve better glycemic control and address multiple aspects of diabetes pathology.
Market Competition: The landscape for diabetes medications, including GLP-1 receptor agonists, was becoming more competitive. Competition often drives innovation and may lead to improved treatment options and cost-effectiveness.
LP Information, Inc. (LPI) ' newest research report, the “GLP-1 for Diabetes Industry Forecast” looks at past sales and reviews total world GLP-1 for Diabetes sales in 2024, providing a comprehensive analysis by region and market sector of projected GLP-1 for Diabetes sales for 2025 through 2031. With GLP-1 for Diabetes sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world GLP-1 for Diabetes industry.
This Insight Report provides a comprehensive analysis of the global GLP-1 for Diabetes landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on GLP-1 for Diabetes portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global GLP-1 for Diabetes market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for GLP-1 for Diabetes and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global GLP-1 for Diabetes.
This report presents a comprehensive overview, market shares, and growth opportunities of GLP-1 for Diabetes market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Injection
Oral Agent
Segmentation by Application:
Woman
Man
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Key Questions Addressed in this Report
What is the 10-year outlook for the global GLP-1 for Diabetes market?
What factors are driving GLP-1 for Diabetes market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do GLP-1 for Diabetes market opportunities vary by end market size?
How does GLP-1 for Diabetes break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
105 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for GLP-1 for Diabetes by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for GLP-1 for Diabetes by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
